Eleonora Trotta, PhD

Postdoctoral Scholar
Diabetes Center
Publications: 

Engineering a Single-Agent Cytokine/Antibody Fusion That Selectively Expands Regulatory T Cells for Autoimmune Disease Therapy.

Journal of immunology (Baltimore, Md. : 1950)

Spangler JB, Trotta E, Tomala J, Peck A, Young TA, Savvides CS, Silveria S, Votavova P, Salafsky J, Pande VS, Kovar M, Bluestone JA, Garcia KC

Revisiting IL-2: Biology and therapeutic prospects.

Science immunology

Abbas AK, Trotta E, R Simeonov D, Marson A, Bluestone JA

A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism.

Nature medicine

Trotta E, Bessette PH, Silveria SL, Ely LK, Jude KM, Le DT, Holst CR, Coyle A, Potempa M, Lanier LL, Garcia KC, Crellin NK, Rondon IJ, Bluestone JA

Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes.

Science (New York, N.Y.)

Sockolosky JT, Trotta E, Parisi G, Picton L, Su LL, Le AC, Chhabra A, Silveria SL, George BM, King IC, Tiffany MR, Jude K, Sibener LV, Baker D, Shizuru JA, Ribas A, Bluestone JA, Garcia KC

IL-2: Change Structure … Change Function.

Immunity

Bluestone JA, Crellin N, Trotta E

The therapeutic potential of regulatory T cells for the treatment of autoimmune disease.

Expert opinion on therapeutic targets

Bluestone JA, Trotta E, Xu D